Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

Abstract: A repaired ex vivo organ suitable for transplantation in a human, said repaired ex vivo organ having undergone ex vivo organ perfusion for a maintenance period, wherein said organ had been assessed as being unsuitable for transplantation into a human before the maintenance period and was determined to be suitable for transplantation after the maintenance period.

Abstract: A system for washing red blood cells, comprising a separator configured to separate a quantity of blood into concentrated red blood cells having a hematocrit of at least 60% and a volume of 150-250 mL, and a supernatant component. The system comprises a flow controller configured to remove the supernatant component to provide an initial red blood cell concentrate; combine 50-500 mL of an additive solution with the red blood cell concentrate to provide an intermediate red blood cell product intended for storage for 42 days or less, wherein the intermediate red blood cell product at the end of storage has an osmolarity value between 202-479 mOsm/L; and wash the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L with a washing solution having an osmolarity value higher than that of the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L.

Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Abstract: A method for the treatment of vernal keratoconjunctivitis in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.

Abstract: The present invention relates generally to polyethylene glycol (PEG) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of the hemoglobin.

Abstract: Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.

Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

Abstract: In various embodiments a reperfusion protection solution (RPS) is provided along with methods of use thereof. Illustrative reperfusion protection solutions include, but are not limited to a buffer; one or more substrates for the synthesis of adenosine triphosphate (ATP) under anaerobic conditions; citrate-phosphate-dextrose (CPD); and one or more amino acids that stabilize cell membranes. Typically the pH of the organ reperfusion protection solution ranges from about pH 8.1 to about pH 8.4.

Abstract: Disclosed are a novel pharmaceutical composition and use thereof, the novel pharmaceutical composition at least comprising an effective amount of mitochondria and at least one pharmaceutically acceptable carrier; the novel pharmaceutical composition is administered to an individual to send the mitochondria into injured or subject-to-oxidative-stress lung cells; thus treating or improving lung injury or related diseases thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.

Abstract: A method prepares a solution of human albumin by reducing dissolved oxygen in a solution of albumin until a concentration of oxygen equal to or less than 0.5 ppm is achieved. A solution of human albumin having a redox state closer to the redox state of the albumin present in human plasma can be achieved.

Abstract: A method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture. The composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate. The magnetic substrate may be characterized by a magnetic susceptibility greater than zero. The composition may also include a chargeable silicon-containing compound. The chargeable silicon-containing compound may coat at least a portion of the magnetic substrate. The biological sample may include cells and/or cellular structures. The method may also include applying a magnetic field to the mixture to manipulate the composition.

Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.

Abstract: Methods and systems for measuring and using the oxidation-reduction characteristics of a biological sample are provided. The system generally includes a test strip and a readout device. A fluid sample is placed in the test strip, and the test strip is in turn operatively connected to the readout device. The readout device provides a controlled current that is sent across the fluid in the sample chamber. In addition, the readout device identifies an inflection point or transition time at which the voltage between contacts of the test strip is changing at the highest rate. The oxidation-reduction capacity of the sample is taken as the integral of the current profile from the time at which current begins to be supplied to the sample to the identified transition time.

Abstract: A kit for altering allogeneic human cells for a human recipient where the kit includes a set of lentivirus vectors where each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and where the set of lentivirus vectors includes individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch and where the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient.

Abstract: An embodiment of the invention is directed to a bone marrow aspiration device comprising a plurality of syringes, each of which operates in a series of sequential steps to obtain bone marrow of high quality and therapeutic value, i.e., having a high mesenchymal stem cell (“MSC”) MSC/ml number. In certain embodiments, a syringe may be used along with a collection vessel or with a second syringe. A further embodiment of the invention is directed to a method for using the bone marrow aspiration device as set forth herein.

Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described.

Abstract: The present invention relates to a method for retrieving more numerous, viable and efficient stem cells from the blood of a patient. The method comprises a preliminary step of pre-treating blood cells using an oxygen-ozone mixture and a subsequent step of separating the stem cells from said pre-treated blood cells.

Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. For example, in some embodiments, tissue patches are made by applying a compressive force to a liquid medium comprising fibrinogen (and/or fibrin) between two surfaces (e.g., within a syringe or other chamber). A filter can be placed within or near the volume in which the compressive force is applied to the liquid medium such that unwanted material (e.g., water, blood cells, and the like) is passed through the filter while desirable components (e.g., fibrin, fibrinogen, and/or other desirable components) are retained by the filter to form the patch. In this way, the concentration of fibrin (and/or fibrinogen) within the liquid medium can be increased, potentially dramatically, as the compressive force is applied to the liquid-containing composition.

Abstract: Methods and systems for processing and conditioning red blood cells are disclosed. The methods and systems may be used to make a readily transfusible red blood cell product with reduced plasma. In general, the plasma content of the supernatant of the red blood cell product is no greater than about 15%. The red blood cell products are prepared using the disclosed methods and systems remain transfusible for up to 42 days.

Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.

Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.

Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.

Abstract: Disclosed herein are methods for cryopreserving cells and tissues under clinical conditions, allowing production of viable cell products suitable for transplantation.

Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Abstract: Apparatuses and systems for removing heavy hydrocarbons from a solvent stream are disclosed herein. The apparatuses extract heavy hydrocarbons into light hydrocarbons and provide a solvent stream having the heavy hydrocarbons removed. Two water washing steps are used to remove residual solvent from the heavy hydrocarbon solution in light hydrocarbons. In some embodiments, the second water wash is used for processing subsequent batches of the solvent stream. The heavy hydrocarbons and solvent can be recovered and processed further. Methods for removing heavy hydrocarbons from a solvent stream are also disclosed herein.

Abstract: An embodiment of the invention is directed to a bone marrow aspiration device comprising a plurality of syringes, each of which operates in a series of sequential steps to obtain bone marrow of high quality and therapeutic value, i.e., having a high MSC/ml number. An embodiment of the invention preferably comprises three syringes, wherein a first syringe is used to aspirate bone marrow from a subject, a second syringe contains an anticoagulant, and the third syringe contains a mixture of the bone marrow aspirate and the anticoagulant.

Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.

Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.

Abstract: Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.

Abstract: The present invention relates to compositions and methods of inducing angiogenesis and methods of treating a pathology that would benefit from angiogenesis by use of a composition comprising partially purified intact mitochondria and/or ruptured mitochondria derived therefrom.

Abstract: The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids (e.g., blood or cerebrospinal fluid, CSF) in two stages characterized by removing a body fluid (e.g., blood or CSF) from a living body diseased with a type of cancer, passing the body fluid through a first stage of applying a treatment to at least one antigen in the body fluid. More specifically, the treatment comprises creating an antibody-antigen moiety during passage thereof through said first stage, passing the treated body fluid through a second stage, removing antibody-antigen moiety from the body fluid during passage through the second stage, and returning the purified body fluid to the body.

Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

Abstract: Method for providing a biocompatible bone implant adapted to fill a bone cavity or lacuna including the steps of providing granular elements in form of granules and/or granule aggregates, providing at least one primary polymeric solution including a biopolymer, at least partly coating the granular elements with the primary polymeric solution, obtaining coated granular elements including a biopolymer coating, providing a cross-linking solution, dipping the coated granular elements in the cross-linking solution, waiting a period of time referred to as “jellification time” of between 30 seconds and 1 hour, in which during said waiting step there occurs the cross-linking of the biopolymer coating of the granular elements with the cross-linking solution and the jellification of the coating, with the aim of obtaining a cohesive biocompatible implant including granular elements and a bio-reabsorbable biopolymer gel; biocompatible bone implant obtained through such method.

Abstract: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.

Abstract: Formulations, mixtures, compositions and techniques for improved treatment options for osteoarthritis and intra-articular joint degeneration. The formulations and compositions are provided in the form of injectable aqueous formulations that increase the delivery of a lubricating agent (lubrication molecules) into the joint to resist breakdown, decrease free radical production (by neutralizing these radicals), and increase removal of superoxide byproducts in the synovial fluid. The injectable aqueous formulations are preferably administered into the intra-articular space of an intra-articular joint. The lubricating formulation includes molecules of lubricin and SOD, hyaluronic acid and SOD, or lubricin and SOD and hyaluronic acid, or hyaluronic acid and lubricin, or Vitamin E and SOD or hyaluronic acid, or combinations thereof.

Abstract: Menstrual fluid simulants may consistently emulate the physical characteristics of real menstrual fluid, including but not limited to, viscosity, stringiness, surface tension and size and concentration of particulate matter. In addition, the constituents comprising the menstrual fluid simulants may be changed in order to mimic the variations in real menstrual fluid observed from woman to woman and from an individual woman over time. The menstrual fluid simulants are of use in the testing of personal care absorbent products.

Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.

Abstract: The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a reaming device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include biodegradable-material based filters and may allow direct implantation of small scale and larger scale matter in specific portions within the biodegradable-material itself.

Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Abstract: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.

Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.

Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.